Skip to main content
. 2022 Jun 10;56(5):689–697. doi: 10.1007/s43441-022-00422-z

Table 6.

CDxs targeting BRCA1 and BRCA2 mutation for ovarian cancer

FDA-approved companion diagnostic FDA-approved therapeutic products
Lynparza® (olaparib) Rubraca® (rucaparib) Zejula ® (niraparib)
BRACAnalysis CDx x x
FoundationFocus CDx BRCA assay x
Myriad myChoice CDx x x
FoundationOne Liquid CDx x